Kate Dixon, M1, Class of 2023
The world of health policy has been consumed with the concern of drug prices – just absolutely and utterly offended by the list price of brand name drugs. How could you not be? When you have drugs like Zolgensma – a brand new drug approved to treat spinal muscular atrophy – running $2.1 million for a single treatment course, it’s pretty easy to throw blame at Big Pharma for the egregious state of the United States’ health care spending. However, when you zoom out and compare drug spending to other expenditures in the vast and complex world of US health care, it becomes pretty clear where the true financial abuse is present – Big Name Hospitals.
Continue reading “The Refocused Health Policy Sandstorm”